The Gap (NYSE:GPS) reported Q4 earnings and revenue that were mixed. The Gap net income for the 13 weeks ended February 1, 2014 was $307 million, or $0.68 per share on a diluted basis. This compares with net income of $351 million, or $0.73 per share on a diluted basis, for the 14 weeks ended February 2, 2013. The Gap reported revenue of $4.57 billion, down from $4.73 billion a year prior.

The Street expected income of $0.66 per share on revenue of $4.6 billion, according to Capital IQ estimates. The company expects earnings per share to be in the range of $2.90 to $2.95 for fiscal year 2014, which is below the Street view of $3.04. Gap will increase the company’s annual dividend to $0.88 in fiscal year 2014, a 10% increase from the company’s current annualized rate of $0.80. This represents more than a 75% increase in the company’s annual dividend per share in the last two years.

YuMe (NYSE:YUME) says Q4 sales were $54 million, up 19% from a year ago but below the Thomson Reuters mean for $59.51 million. Net income was $0.16 per share, a penny ahead of estimates. It sees Q1 sales between $35.0 million – $36.0 million and 2014 sales between $190 million – $200 million.

Acadia Pharmaceuticals (NASDAQ:ACAD) reported a net income loss of $12.0 million, or $(0.13) per share for Q4 2013, beating the estimate for a loss of $0.14. Revenue of $37,000 missed estimates of $310,000 and were down 90% from the same quarter last year. Shares of ACAD are down 2% in after-hours trading with a 52-week range of $5.86 to $31.45.

Ross Stores Inc. (NASDAQ:ROST) fell 3.2% in late trading after the company provided Q1 guidance that was below analyst estimates. The store chain estimated Q1 earnings would rise 4% to 7% from a year earlier to a range of $1.11 to $1.15 a share, compared with the Capital IQ estimate of $1.20. Ross said Q4 earnings were $1.02 a share for a 13-week sales period, matching the Capital IQ estimate of $1.02. The company posted earnings of $1.07 a year ago during a 14-week sales period.

Q4 revenue was $2.74 billion, compared with the consensus estimate of $2.7 billion. Comparable store sales rose 2% from a year earlier. Wedbush Securities Inc. began coverage of Ross this morning with an Outperform rating and a price target of $83. The stock declined 3.2% to a $70.01 a share. It reached a 52-week high of $81.99 on November 18.